Sacituzumab Tirumotecan for Breast Cancer

(BERLIN Trial)

This trial tests the effectiveness of sacituzumab tirumotecan, a new treatment for people with triple-negative breast cancer that has spread to the brain. This type of breast cancer lacks the three common receptors that typically fuel its growth. The trial aims to determine if this drug can help manage or slow cancer progression in these patients. It may suit those diagnosed with this specific breast cancer type and have brain metastases that are untreated or worsening after previous treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people, offering hope for managing this challenging condition.

The trial requires a washout period (time without taking certain medications) for some treatments before starting. For example, you need to stop strong CYP3A4 inducers/inhibitors 2 weeks before the trial. It's best to discuss your specific medications with the trial team to see if any adjustments are needed.

Research has shown that sacituzumab tirumotecan generally presents manageable side effects for patients. In some studies, 57.7% to 63.4% of patients experienced serious side effects. The most common serious side effects include low levels of certain blood cells, which help fight infections and carry oxygen. Less serious side effects, such as nausea and hair loss, are also common but usually mild. Despite these risks, the treatment has demonstrated promising results in controlling cancer growth, especially when compared to traditional chemotherapy.¹²³⁴⁵

Sacituzumab tirumotecan is unique because it combines an antibody with a potent chemotherapy agent, specifically targeting cancer cells in breast cancer. Unlike standard treatments like hormone therapy or traditional chemotherapy, this drug delivers chemotherapy directly to the cancer cells, minimizing damage to healthy cells. Researchers are excited about its potential to improve effectiveness and reduce side effects compared to conventional treatments.

Research has shown that sacituzumab tirumotecan, the treatment under study in this trial, holds promise for treating advanced triple-negative breast cancer that has spread (mTNBC). Studies have found that this treatment helps patients live longer without their cancer worsening. Specifically, earlier research indicated that patients lived longer on average compared to those receiving traditional chemotherapy. The treatment also demonstrated a higher success rate in shrinking tumors compared to standard options. This evidence suggests that sacituzumab tirumotecan could be an effective choice for people with advanced mTNBC.²⁴⁶⁷⁸